Thank you for joining!



We will begin in just a few minutes



www.DietID.com

Diet ID – FREE ACCESS

In response to the impact of Covid-19 and the transition to digital care

- Digital Dietary Assessment + Goal Setting
- Completed in 2 minutes
- Real-time results
- Data include nutrient intake, food group intake, HEI score, sample meal plans, and more
- Your own branded web app in 24 hours





HOW DO LIFESTYLE-RELATED CONDITIONS AFFECT COVID-19 OUTCOMES?

David L. Katz, MD, MPH

CEO, Diet ID; President, True Health Initiative

Candace D. McNaughton, MD, PhD, MPH

Associate Professor, Emergency Medicine, Vanderbilt University Medical Center

Robert J. Ostfeld, MD, MSc, FACC

Director of Preventive Cardiology, Montefiore Health System

May 20, 2020

CHRONIC DISEASES IN AMERICA

6 IN 10

Adults in the US have a **chronic disease**



4 IN 10

Adults in the US have **two or more**

THE LEADING CAUSES OF DEATH AND DISABILITY and Leading Drivers of the Nation's **\$3.5 Trillion** in Annual Health Care Costs





www.DietID.com <u>https://www.cdc.gov/chronicdisease/resources/infographic/chronic-diseases.htm</u>

Prevalence in the US (Adults)

- Obesity: 43% (Severe obesity: 9%)
- Diabetes: 11% of the population; 27% of seniors (>65)
- CVD: 48%
- Hypertension: 45%
- Metabolic syndrome: 24%; 44% in those over 50



Main Determinants of Mortality Risk







Statistics

www.DietID.com

- 94% of deaths from COVID-19 are in those with an underlying age-related chronic disease
- Adjusting for other risk factors, Americans with obesity (BMI>30) have a more than four times higher risk of hospitalization due to coronavirus, while those with severe obesity (BMI>40) have a more than six times higher risk
- Experts warn that healthy people have had severe infection (viral dose? genetics?) – avoid being overly reassured

Hyman M, Mozaffarian D. The link between coronavirus deaths and those french fries. Opinion: The Boston Globe. May 7, 2020. <u>https://www.bostonglobe.com/2020/05/07/opinion/link-between-coronavirus-deaths-those-french-fries/</u> Docherty AB, Harrison EM, Green CA, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv 2020.04.23.20076042; doi: https://doi.org/10.1101/2020.04.23.20076042



Underlying Conditions in COVID-19

- In general, "comorbidity" refers to the simultaneous presence of >1 chronic disease or condition in a patient.
- In COVID-19, the most common comorbidities related to poor outcomes (hospitalizations, morbidity) are:
 - Hypertension
 - Diabetes
 - Cardiovascular disease
 - Respiratory system disease
 - Obesity





Percentage of COVID-19-associated hospitalizations in the U.S. from March 1 to 30, 2020 with select with underlying conditions

Chronic obstructive pulmonary disease Sources MMWR; CDC; US Department of Health and Cardiovascular disease Human Services © Statista 2020 Coronary artery disease Congestive heart failure Additional Information: United States; MMWR; CDC; March 1 to 30, 2020; 18 years and older Neurologic disease Renal disease Immunosuppressive condition https://www.stati Gastrointestinal/Liver disease sta.com/statistics Blood disorder /1111428/covidhospitalization-Rheumatologic/Autoimmune disease underlying-Pregnancy conditions-us/



WEBINAF

SERIES

Brought to you by Diet ID

Defining Comorbidities in COVID-19

"We estimate 56.0% of US adults are at risk of needing hospitalization for COVID-19 due to underlying conditions. Such estimates will vary depending on exact criteria used to define underlying conditions but represent a substantial fraction of all US adults. These underlying conditions are, in turn, associated with modifiable risk factors including ever smoking, being sedentary and inadequate fruit and vegetable consumption. The three risk factors were estimated to contribute 40.6% of attributable-risk for all adults reporting any of the underlying conditions in this study including 34.2% of attributablerisk among adults ages 18-59 and 59.7% for adults ages 60 and older. These results suggest the potential for policies based on risk-stratification of the population and for possible improvement of risk status through lifestyle change. A national focus on, and support for, a "health promotion" campaign would be timely."

www.DietID.com

Adams ML, Grandpre J, Katz DL. Updated estimates of comorbidities associated with risk for COVID-19 complications based on US data. medRxiv 2020.05.02.20088781; doi: https://doi.org/10.1101/2020.05.02.20088781



Sample of 5700 Pts Hospitalized with COVID in NYC

Richardson S, Hirsch JS, Narasimhan M, et a. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020; April 22; https://jamanetwork.com/jour nals/jama/fullarticle/2765184

www.DietID.com

Table 1. Baseline Characteristics of Patients Hospitalized With COVID-19

		No. (%)
Demo	ographic information	
Total No.		5700
Age, median (IQR) [range], y		63 (52-75) [0-107]
Sex		
Fer	male	2263 (39.7)
Ma	le	3437 (60.3)
Racea	3	
No		5441
Afr	rican American	1230 (22.6)
Asi	ian	473 (8.7)
Wh	lite	2164 (39.8)
Oth	her/multiracial	1574 (28.9)
Ethnicity ^a		
No		5341
His	spanic	1230 (23)
No	n-Hispanic	4111 (77)
Pre	eferred language non-English	1054 (18.5)
Insura	ance	
Сог	mmercial	1885 (33.1)
Me	dicaid	1210 (21.2)
Me	dicare	2415 (42.4)
Sel	lf-pay	95 (1.7)
Oth	her ^b	95 (1.7)



Sample of 5700 Pts Hospitalized with COVID in NYC

Richardson S, Hirsch JS, Narasimhan M, et a. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020; April 22; https://jamanetwork.com/jour nals/jama/fullarticle/2765184

	No. (%)	
Comorbidities	(Me
Total No.	5700	(
Cancer	320 (6)	_
Cardiovascular disease		1
Hypertension	3026 (56.6)	ī
Coronary artery disease	595 (11.1)	Ne
Congestive heart failure	371 (6.9)	
Chronic respiratory disease		Co
Asthma	479 (9)	i
Chronic obstructive pulmonary disease	287 (5.4)	-
Obstructive sleep apnea	154 (2.9)	3
Immunosuppression		1
HIV	43 (0.8)	(
History of solid organ transplant	55 (1)	^a Race a
Kidney disease		catego Other i
Chronic ^c	268 (5)	- Assess Interno
End-stage ^d	186 (3.5)	Tenth I Assess ¹
Liver disease	e	by ICD ^a Assess
Cirrhosis	19 (0.4)	diet-co Comor
Chronic		history presen
Hepatitis B	8 (0.1)	ⁱ Charlso on age
Hepatitis C	3 (0.1)	mortal

	No. (%)
Metabolic disease	\frown
Obesity (BMI ≥30)	1737 (41.7)
No.	4170
Morbid obesity (BMI ≥35)	791 (19.0)
No.	4170
Diabetes ^e	1808 (33.8)
Never smoker	3009 (84.4)
No.	3567
Comorbidities ^f	
None	350 (6.1)
1	359 (6.3)
>1	4991 (88)
Total, median (IQR)	4 (2-8)
Charlson Comorbidity Index score, median (IQR) ^g	4 (2-6)

Race and ethnicity data were collected by self-report in prespecified fixed categories.

Other insurance includes military, union, and workers' compensation.

Assessed based on a diagnosis of chronic kidney disease in medical history by International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) coding.

Assessed based on a diagnosis of end-stage kidney disease in medical history by *ICD-10* coding.

Assessed based on a diagnosis of diabetes mellitus and includes diet-controlled and non-insulin-dependent diabetes.

Comorbidities listed here are defined as medical diagnoses included in medical history by *ICD-10* coding. These include, but are not limited to, those presented in the table.

Charlson Comorbidity Index predicts the IO-year mortality for a patient based on age and a number of serious comorbid conditions, such as congestive heart failure or cancer. Scores are summed to provide a total score to predict mortality. The median score of 4 corresponds to a 53% estimated 10-year survival and reflects a significant comorbidity burden for these patients.



Clinical Observations

- What is the "typical patient"?
- How quickly / easily can clinicians predict outcomes risk?
- Are people with uncontrolled T2D or HTN at greater risk than those controlling it with medication?
- Learnings from direct observations
- Thoughts about how healthcare providers should adjust future focus of care



Assessing Risk

- Many models evaluate risk based on available data
- Researchers develop tools to quickly determine at-risk patients and predict lethality, based on age, conditions, age of diagnosis, and other factors
- Enables clinicians to stratify risk and determine best course of management / treatment

Bello-Chavolla OY, Bahena-Lopez JP, Antonio-Villa NE, et al. Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. medRxiv 2020.04.20.20072223; doi: <u>https://doi.org/10.1101/2020.04.20.20072223</u>



OBESITY





WEBINAR SERIES FOOD TRUTHS

https://www.fron tiersin.org/article s/10.3389/fpubh. 2020.00135/full



Covid-19: Death through virally-driven hyperinflammation.

Adipose tissue is populated by a number of immune cells including T cells and macrophages.















Obesity

- How does obesity increase COVID risk?
 - Associated with metabolic syndrome and inflammation
 - Increased weight compresses the lungs
 - Predisposition to pulmonary dysfunction
 - Increases risk of acute respiratory distress syndrome
- In young patients (<50), obesity is the single largest predictor of severe illness and death



HYPERTENSION



Hypertension

www.DietID.com

- How does hypertension increase COVID risk?
 - Hypertension indicative of other chronic inflammatory conditions
 - Already taxed blood vessels have to work extra hard to circulate oxygen
 - It's been suggested that ACE inhibitors and ARBs may increase susceptibility to infection, but currently the risk/benefit clearly favors using the meds to control blood pressure. RTCs in progress.



https://www.health.harvard.edu/blog/how-does-cardiovascular-disease-increase-the-risk-of-severe-illness-and-death-from-covid-19-2020040219401

Jarcho JA, Ingelfinger JR, Hamel MB. Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19. NEJM 2020. https://doi.org/10.1056/NEJMe2012924

DIABETES



Diabetes

- How does diabetes increase COVID risk?
 - Hyperglycemia causes immune response dysfunction
 - Damaged circulatory system compromises blood flow and oxygen delivery
 - Higher affinity of cellular binding and efficient virus
 - Decreased viral clearance in the blood stream
 - Diminished T cell function
 - Increased susceptibility to hyper-inflammation and cytokine storm syndrome



https://www.clinicalomics.com/news-and-features/diabetic-

www.DietID.com

patients-at-higher-risk-for-covid-19-mortality/

Diabetes Outcomes Study (Hubei, China)

Zhu L, She ZG, Cheng X et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metabolism 2020; <u>https://doi.org/10.1016/j.cmet.2020.</u> 04.021



Diabetes Outcomes Study (Hubei)

- 7337 cases, 952 with pre-existing T2D
- T2D pts mortality rate 7.8% vs 2.7%
- T2D pts more at risk for multiple organ injury
- Among T2D pts, risk largely dependent upon blood glucose control
- Diabetes status predicts need for medical interventions as well as mortality

Zhu L, She ZG, Cheng X et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metabolism 2020; <u>https://doi.org/10.1016/j.cmet.2020.04.021</u>



Diabetes Outcomes Study (USA)

- 451 pts with diabetes (among a sample of 1122)
- T2D patients had a 4x higher death rate from COVID-19
- Mortality rate for T2D patients was 28.8% (compared to 6.2% without diabetes in the sample)
- Those with uncontrolled hyperglycemia had highest mortality rate (41.7%)

Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. Journal of Diabetes Science and Technology 2020. <u>https://glytecsystems.com/wp-content/uploads/JDST-Glytec-</u> Covid-Research.pdf



CARDIOVASCULAR DISEASE



Cardiovascular disease

- How does CVD increase COVID risk?
 - Viral illness increases demand on the heart (e.g. fever, rapid heart rate)
 - Compromised oxygen distribution
 - Inflammation of the already damaged heart (myocarditis)
 - CVD pts more susceptible to clots, heart attack, stroke caused by viral-induced inflammation
- CVD patients have a 10x greater risk of death from COVID-19 than healthy patients



https://www.health.harvard.edu/blog/how-does-cardiovascular-diseaseincrease-the-risk-of-severe-illness-and-death-from-covid-19-2020040219401

Putting it all together: INFLAMMATION

- Inflammation is the underlying consequence and driver of essentially all chronic disease
- Increases risk of cytokine storm, leading to poor outcomes
- Obesity and poor metabolic health cause increased inflammation and immune suppression
- SAD diet contributes to chronic inflammation



Poor nutrition: modifiable risk factor

Obesity Insulin Resistance Diabetes Hypertension Heart Disease

Metabolic Impairment

S

0

D

A

Compromised Immune Function HIGH RISK / POOR OUTCOMES

From Slow Motion To Acute Worry

- Most lifestyle-related diseases happen over decades
- The risk is there, but not addressed because most can "buy time"
- COVID-19 era: The risk is still there, but it's scarier
- People are motivated to decrease risk of severe infection
- DIET and LIFESTYLE adjustments can reduce risk AND improve health over time, by doing the same things.







NYC COVID-19 Deaths Among Confirmed Cases

No Underlying Underlying Underlying Conditions Total Conditions¹ Conditions Unknown Age Group - 0 to 17 8 10 1 1 - 18 to 44 495 19 111 625 3011 71 - 45 to 64 474 3556 - 65 to 74 3143 3 817 3963 2 75 and over 5913 1816 7731 0 2 3 Unknown 1 Sex 4985 11 1227 6223 - Female - Male 7563 85 1986 9634 31 - Unknown 23 0 8

$\Sigma = 15,888$

WEBINAR SERIES FOOD TRUTHS

https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-19-daily-datasummary-deaths-05172020-1.pdf Available data as of May 20, 2020

Risk in Children

- Infection/recovery rate unknown (asymptomatic children generally not tested)
- Report summary from China 72,314 cases, 1% under 10 years old, 1% aged 10-19.
- Italy data 2 of the 30k deaths were those under age 19 (0.0067% of total deaths)
- JAMA study: 48 children ≤21y in PICU (US + Canada)
 - 40 had underlying medical conditions (15% obese, 8% diabetes, 23% immune suppression or malignancy)
 - 4.2% mortality rate

Zunyou W, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239-1242. 10.1001/jama.2020.2648

www.DietID.com

Shekerdemian LS et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. JAMA Pediatrics 2020. May 11.



Risk in Children

- Rare Kawasaki-like condition (pediatric multi-system inflammatory syndrome) but not the same
 - Sx=fever, rash, red eyes, swollen lymph nodes, abdominal pain
 - Risk=toxic shock, low BP, poor circulation

https://doi.org/10.1001/jamapediatrics.2020.1948

- May be a post-infection process
- NY state: 3 died from the syndrome
 - NYC Study-147 cases of PMIS, 69 with COVID infection or antibodies
- No other deaths reported in the US outside of NY as of 5/17/20



www.DietID.com

https://www.nytimes.com/article/kawasaki-disease-coronavirus-children.html https://www.nytimes.com/2020/05/12/well/family/coronavirus-children-covid-19.html https://www.cdc.gov/mmwr/volumes/69/wr/mm6914e4.htm https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19

Risk in Children

- Infected children are likely less contagious to others than adults (transmission from children to adults appears rare), and may be less likely to become infected upon exposure
- Pedi ER visits are down; may delay critical treatment
- Immunizations are down, leading to other risks of infectious disease



Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic Population. NEJM 2020. https://doi.org/10.1056/NEJMoa2006100https://www.nytimes.com/2020/05/12/well/family/coronavirus-children-covid-19.html https://www.nytimes.com/2020/05/05/nyregion/children-Kawasaki-syndrome-coronavirus.html

Clinical Implications

- Do patients with lifestylerelated comorbidities have a different treatment plan than those without?
- What do we know, if anything, about long-term effects among survivors with comorbidities?





Conclusions

- Candace McNaughton
- Robert Ostfeld
- David Katz



QUESTION & ANSWER



Please submit questions via Q/A feature



Thank you for attending!



We'll send out an announcement about our next webinar. Make sure you're on our email list!